Hansa Biopharma, a company involved in immunomodulatory enzyme technology for rare IgG mediated diseases, has named Professor Achim Kaufhold as its new chief medical officer, it was reported on Friday.
Kaufhold has served as CMO and member of the Executive Committee at Basilea Pharmaceutica in Switzerland. He is a senior pharmaceutical executive within immunology, infectious diseases and oncology.
Soren Tulstrup, president and CEO, Hansa Biopharma, said, 'I am very happy that we have managed to attract Achim Kaufhold as CMO. 2020 promises to be a transformative year for our company with the potential EU regulatory approval of imlifidase in kidney transplantation and top line data from the first phase 2 trial in autoimmune diseases.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca